Trial Profile
A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Malignant Melanoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jun 2015
Price :
$35
*
At a glance
- Drugs Dorgenmeltucel-L (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 22 Mar 2008 New trial record.